Notas del episodio
Essential listening for biotech investors: Host Carmel Fisher interviews Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), who has a proven track record of generating multi-billion dollar returns in biotech.
Investment Thesis: Dr. Trieu previously delivered $2.9 billion (Abraxane®/Celgene) and ...
Palabras clave
biosciences
otcmarkets
carmel fisher
OTCQB
the harvest podcast
the harvest
biotech
biopharma
pharmaceuticals
harvest communications
capital markets
biotherapeutics
ceo interviews
investment portfolio
BiotechInvesting
abraxane
patents
cynviloq
Dr. Trieu
$OTLC
Oncotelic Therapeutics
regulatory announcements
milestones
late-stage assets
portfolio diversification